Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Sham Intervention, Survey Administration, Transcranial Direct Current Stimulation.
- Who it may be relevant to
- Registry conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex
Overview
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.
Interventions
- Procedure Sham Intervention
Undergo sham tDCS - Other Survey Administration
Ancillary studies - Device Transcranial Direct Current Stimulation
Undergo tDCS
Primary outcome measures
- Vibration detection threshold [Time frame: at weeks 2 and 3]
Secondary outcome measures (2)
- Cold detection threshold [Time frame: at weeks 2 and 3]
- Correlation between executive function and chemotherapy-induced peripheral neuropathy (CIPN) severity [Time frame: At baseline]
Eligibility criteria
Inclusion criteria
- 18 to 85 years of age
- Diagnosis of cancer, stages I-IV
- Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)
- Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy
- CIPN20 score ≥ 20
- Able to walk unassisted
- Proficient in English
Exclusion criteria
- Known brain metastases
- Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)
- History of brain or spinal surgery
- Neuropathy other than CIPN
- Significant hearing or vision deficits
- Vestibulopathy
- Currently receiving chemotherapy, radiation therapy, or immunotherapy
- Contraindications to transcranial direct current stimulation (tDCS), including recent seizures
- Presence of metallic objects in the head
- Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)
- Active scalp dermatological conditions
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple blind
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- University of Michigan Rogel Cancer Center — Ann Arbor
Identifiers
NCT: NCT07673614 · UMCC 2025.097 · NCI-2026-03995 · HUM00276508